Last updated on January 2018

An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder


Brief description of study

An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Detailed Study Description

This study will evaluate the long-term safety and tolerability of rapastinel as an adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD).

Clinical Study Identifier: TX148002

Contact Investigators or Research Sites near you

Start Over

Colleen Figueroa

University of South Florida-Morsani College of Medicine
Tampa, FL USA
  Connect »